Monthly Archives: December 2016

Safety advisory – risk of hepatitis B virus reactivation

19 December 2016 Consumers and Healthcare Professionals are advised that direct-acting antiviral (DAA) medicines for the treatment of chronic hepatitis C virus (HCV) infection have been associated with reactivation of hepatitis B virus (HBV) in patients with a current or previous HBV infection. A recent TGA review of the available data, including data from international […]